A comment on ‘Development of the Gastrointestinal Dysfunction Score (GIDS) for critically ill patients e A prospective multicenter observational study (iSOFA study)’ (Reintam et al 2021. Clinical Nutrition, V 40 (8):p 4932-4940)

2021 ◽  
Author(s):  
Varsha M. Asrani ◽  
Colin McArthur ◽  
Ian Bissett ◽  
John A. Windsor
Keyword(s):  
Observational Study ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Clinical Nutrition ◽  
Gastrointestinal Dysfunction ◽  
Multicenter Observational Study ◽  
Prospective Multicenter Observational Study

Respiratory Viruses in Invasively Ventilated Critically Ill Patients—A Prospective Multicenter Observational Study

2018 ◽  
Vol 46 (1) ◽  
pp. 29-36 ◽  
Author(s):  
Frank van Someren Gréve ◽  
Nicole P. Juffermans ◽  
Lieuwe D. J. Bos ◽  
Jan M. Binnekade ◽  
Annemarije Braber ◽  
...  
Keyword(s):  
Observational Study ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Respiratory Viruses ◽  
Multicenter Observational Study ◽  
Prospective Multicenter Observational Study

scholarly journals Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study

2019 ◽  
Vol 70 (9) ◽  
pp. 1837-1844 ◽  
Author(s):  
Yaseen M Arabi ◽  
Sarah Shalhoub ◽  
Yasser Mandourah ◽  
Fahad Al-Hameed ◽  
Awad Al-Omari ◽  
...  
Keyword(s):  
Middle East ◽  
Observational Study ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Structural Model ◽  
Middle East Respiratory Syndrome ◽  
Time Varying ◽  
Marginal Structural Model ◽  
Recombinant Interferon ◽  
Multicenter Observational Study

Abstract Background The objective of this study was to evaluate the effect of ribavirin and recombinant interferon (RBV/rIFN) therapy on the outcomes of critically ill patients with Middle East respiratory syndrome (MERS), accounting for time-varying confounders. Methods This is a retrospective cohort study of critically ill patients with laboratory-confirmed MERS from 14 hospitals in Saudi Arabia diagnosed between September 2012 and January 2018. We evaluated the association of RBV/rIFN with 90-day mortality and MERS coronavirus (MERS-CoV) RNA clearance using marginal structural modeling to account for baseline and time-varying confounders. Results Of 349 MERS patients, 144 (41.3%) patients received RBV/rIFN (RBV and/or rIFN-α2a, rIFN-α2b, or rIFN-β1a; none received rIFN-β1b). RBV/rIFN was initiated at a median of 2 days (Q1, Q3: 1, 3 days) from intensive care unit admission. Crude 90-day mortality was higher in patients with RBV/rIFN compared to no RBV/rIFN (106/144 [73.6%] vs 126/205 [61.5%]; P = .02]. After adjusting for baseline and time-varying confounders using a marginal structural model, RBV/rIFN was not associated with changes in 90-day mortality (adjusted odds ratio, 1.03 [95% confidence interval {CI}, .73–1.44]; P = .87) or with more rapid MERS-CoV RNA clearance (adjusted hazard ratio, 0.65 [95% CI, .30–1.44]; P = .29). Conclusions In this observational study, RBV/rIFN (RBV and/or rIFN-α2a, rIFN-α2b, or rIFN-β1a) therapy was commonly used in critically ill MERS patients but was not associated with reduction in 90-day mortality or in faster MERS-CoV RNA clearance.

Sign in / Sign up

Export Citation Format

Share Document